NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Extracorporeal Membrane Oxygenation (ECMO) and Coronavirus Disease (COVID) 19

CompletedN/A

Sponsor: Rennes University Hospital

Conditions: ARDS Related to Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 2, Acute Refractory Heart Failure Related to SARS-CoV 2

Countries: France

The role of ECMO in the treatment of patients with severe COVID-19 (Acute Respiratory Distress Syndrome (ARDS) and/or acute refractory heart failure) is not yet known. The present study will aim to report the results of the ECMO management of the most severe forms of COVID-19 through the first French ECMO registry.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* All COVID-19 patients, adults or children,
* Tested positive by RT-PCR for SARS-CoV2 (nasopharyngeal swabs, sputum, endotracheal aspiration, bronchoalveolar lavage or stool sample) and / or with a diagnosis made on chest CT findings,
* Supported by venovenous or venoarterial ECMO

Exclusion Criteria:

* Temporary legally protected Adults over a set period or waiting for protection supervision, guardianship
* Patients or proxies who express their opposition to study participation

Locations (44)

Angers, France
Besançon, France
Brest, France
Caen, France
Clermont-Ferrand, France
Créteil, France
Dijon, France
La Roche-sur-Yon, France
La Tronche, France
Le Kremlin-Bicêtre, France
Le Plessis-Robinson, France
Lens, France
Lille, France
Limoges, France
Lyon, France
Lyon, France
Marseille, France
Marseille, France
Marseille, France
Metz, France
Montpellier, France
Mulhouse, France
Nancy, France
Nantes, France
Neuilly-sur-Seine, France
Nîmes, France
Paris, France
Paris, France
Paris, France
Paris, France
+ 14 more on CT.gov